Terapet & Yonsei Teams. From the left: Laura Acosta, Senior Startup Manager STO Seoul, Terapet and Yonsei teams after successfully completing the installation of Qualyscan at Yonsei Cancer Center.

Terapet Expands in Korea with Successful Installation at Yonsei Cancer Center and Strategic Collaboration

Terapet, a Geneva-based CERN spin-off developing an innovative platform technology for imaging in nuclear medicine, announced in 2024 the successful installation of its end-to-end quality assurance device (Qualyscan) at the Yonsei Cancer Center (Heavy Ion Therapy Center) in October.

This project, which began last year, was launched in collaboration with Terapet’s Korean partners, Yonsei Cancer Center and Onsosoft Inc.. On October 13th 2023, the three parties formalized their partnership by signing a Collaboration Agreement during the FARO-KOSRO 2023 Congress in Seoul. This collaborative project also secured substantial non-dilutive funding of approximately CHF 3’000’000, awarded to the Korean partners through the Innosuisse – KIAT bilateral innovation project.

In line with this development, Terapet transitioned from Innosuisse Market Validation Camp in Korea in 2023 to Market Entry Camp in March 2024.

With the support of Innosuisse, Swiss startups have the opportunity to validate their products, technologies, or solutions in some of the Swissnex locations. Each location offers a unique program to support startups’ global expansion, depending on the industry, stage of development, and, most importantly, their needs and interests in entering the targeted market. The team in Seoul has adopted a tailored approach to support Swiss startups from the initial stage of the camp development, recognizing the challenges that Swiss startups may face in entering the Korean market as foreign entities. Feedbacks confirmed that this approach played a fundamental role in the successful outcome achieved by Terapet.

This success was driven by the transition from validation to market entry, which aimed to gain further support and guidance in navigating the Korean market, facilitating the installation of their Qualyscan device at Yonsei Cancer Center, and exploring opportunities for Nuclycan, Terapet’s novel PET scanner.

Terapet is an outstanding example within the Swiss startup ecosystem, successfully combining cutting-edge technology with a clear vision and transforming Innosuisse support instruments into tangible outcomes.

Yonsei Hospital Cancer Center / Installation of Terapet Qualyscan at Heavy Ion Therapy Center